|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital Eli Lilly and Company Sanofi-Synthelabo Genentech |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00418093 |
The main purpose of this study is to begin to collect information and try to learn whether or not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with recurrent mullerian carcinoma. We will also collect more information about the safety and side effects of this combination of drugs. Gemcitabine and oxaliplatin are chemotherapy drugs that kill cancer cells. Bevacizumab is a new anti-cancer drug that works to slow or stop cell growth in cancerous tumors by decreasing the blood supply to the tumors.
Condition | Intervention | Phase |
Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer |
Drug: Gemcitabine Drug: Oxaliplatin Drug: Bevacizumab |
Phase II |
MedlinePlus related topics: | Cancer Ovarian Cancer |
ChemIDplus related topics: | Gemcitabine hydrochloride Gemcitabine Bevacizumab Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
Estimated Enrollment: | 40 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | September 2008 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Neil Horowitz, MD | 617-724-4800 | nhorowitz@partners.org |
Contact: Anthony Luzzi | 617-726-1634 | aluzzi@partners.org |
United States, Massachusetts | |||||
Massachusetts General Hospital | Recruiting | ||||
Boston, Massachusetts, United States, 02114 | |||||
Principal Investigator: Neil Horowitz, MD | |||||
Dana-Farber Cancer Institute | Recruiting | ||||
Boston, Massachusetts, United States, 02115 | |||||
Principal Investigator: Ursula Matulonis, MD |
Dana-Farber Cancer Institute |
Massachusetts General Hospital |
Brigham and Women's Hospital |
Eli Lilly and Company |
Sanofi-Synthelabo |
Genentech |
Principal Investigator: | Neil Horowitz, MD | Massachusetts General Hospital |
Responsible Party: | Dana-Farber Cancer Institute ( Neil Horowitz, MD ) |
Study ID Numbers: | 04-356 |
First Received: | January 2, 2007 |
Last Updated: | December 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00418093 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|